Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 605

Related Citations for PubMed (Select 18675236)

1.

QT prolongation is an unreliable predictor of ventricular arrhythmia.

Hondeghem LM.

Heart Rhythm. 2008 Aug;5(8):1210-2. doi: 10.1016/j.hrthm.2008.05.006. Epub 2008 May 15.

PMID:
18675236
2.

QT and TdP. QT: an unreliable predictor of proarrhythmia.

Hondeghem LM.

Acta Cardiol. 2008 Feb;63(1):1-7. Review.

PMID:
18372573
3.

A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).

Lu HR, Yan GX, Gallacher DJ.

J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):250-9. doi: 10.1016/j.vascn.2013.01.003. Epub 2013 Jan 19.

PMID:
23337247
4.
5.

Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.

Shah RR, Hondeghem LM.

Heart Rhythm. 2005 Jul;2(7):758-72. Review.

PMID:
15992736
6.

TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).

Hondeghem LM.

Novartis Found Symp. 2005;266:235-44; discussion 244-50. Review.

PMID:
16050272
7.

Nonclinical proarrhythmia models: predicting Torsades de Pointes.

Lawrence CL, Pollard CE, Hammond TG, Valentin JP.

J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):46-59. Review.

PMID:
15975832
8.

[Drug induced QT prolongation].

Altmann D, Eggmann U, Ammann P.

Wien Klin Wochenschr. 2008;120(5-6):128-35. doi: 10.1007/s00508-008-0940-6. Review. German.

PMID:
18365152
10.

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.

Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L.

J Pharmacol Toxicol Methods. 2004 May-Jun;49(3):171-81. Review.

PMID:
15172013
11.

Polymorphous ventricular tachyarrhythmias in the absence of structural heart disease.

Coumel P.

Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 2):2065-7.

PMID:
9272510
12.

QT interval prolongation and ventricular fibrillation in childhood end-stage renal disease.

Kim GB, Cho HY, Kwon BS, Bae EJ, Noh CI, Choi JY, Yun YS, Choi Y, Ha JW.

Int J Cardiol. 2008 Jul 21;127(3):e126-8. Epub 2007 Aug 21.

PMID:
17714808
13.

Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.

Shantsila E, Watson T, Lip GY.

Europace. 2007 Sep;9 Suppl 4:iv37-44. Review.

14.

[Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].

Kecskeméti V.

Neuropsychopharmacol Hung. 2004 Mar;6(1):5-12. Review. Hungarian.

PMID:
15125308
15.

Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?

Holbrook M, Malik M, Shah RR, Valentin JP.

J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):21-8. doi: 10.1016/j.vascn.2008.09.001. Epub 2008 Sep 17.

PMID:
18834945
16.

Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.

Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS.

Prog Biophys Mol Biol. 2006 Jan-Apr;90(1-3):414-43.

PMID:
16321428
17.
18.

QTc prolongation as a surrogate for drug-induced arrhythmias: fact or fallacy?

Hondeghem LM.

Acta Cardiol. 2011 Dec;66(6):685-9.

PMID:
22299377
19.

[QTc-prolonging drugs and the risk of sudden death].

Reingardiene D, Vilcinskaite J.

Medicina (Kaunas). 2007;43(4):347-53. Review. Lithuanian.

20.

Drug-induced QT prolongation and proarrhythmia: an inevitable link?

Ahmad K, Dorian P.

Europace. 2007 Sep;9 Suppl 4:iv16-22. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk